Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent

Int J Biochem Cell Biol. 2008;40(12):2802-14. doi: 10.1016/j.biocel.2008.05.023. Epub 2008 Jun 11.

Abstract

Based on its antiviral activity profile, cyanovirin-N (CV-N) holds great potential for anti-HIV microbicidal application. However, limited data are available on the possible side-effects of this lectin. A detailed investigation was carried out to obtain better insights in the cytotoxic, inflammatory and (anti)-proliferative properties of CV-N in comparison with several other plant-derived lectins. CV-N affected the cell morphology of PBMCs and enhanced the expression of the cellular activation markers CD25, CD69 and HLA-DR. PBMCs activated by CV-N were more susceptible for R5 HIV-1 infection. In addition, CV-N exerted a pronounced mitogenic activity and significantly enhanced in PBMCs the production of a wide variety of cytokines, as determined by the Bio-Plex human cytokine 27-plex array system. In comparison, other lectins obtained from Hippeastrum hybrid, Galanthus nivalis, and Urtica dioica induced markedly less, if any, stimulatory effects. So, the use of CV-N may be accompanied by various stimulatory effects that may compromise its application for microbicidal use.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / virology*
  • Anti-HIV Agents / metabolism
  • Anti-HIV Agents / pharmacology*
  • Bacterial Proteins / adverse effects*
  • Bacterial Proteins / pharmacology
  • Carrier Proteins / adverse effects*
  • Carrier Proteins / pharmacology
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Cytokines / biosynthesis
  • Dose-Response Relationship, Drug
  • HIV / metabolism*
  • HIV Infections / virology*
  • Humans
  • Leukocytes, Mononuclear / drug effects

Substances

  • Anti-HIV Agents
  • Bacterial Proteins
  • Carrier Proteins
  • Cytokines
  • cyanovirin N